Hematopoietic stem cell transplantation for sickle cell disease: State of the science

European Journal of Haematology

Volumn 94, Issue 5, 2015, Pages 391-399

  Talano, Julie An ^a   Cairo, Mitchell S ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Familial haploidentical transplantation; Reduced toxicity conditioning; Sickle cell disease

Indexed keywords

LEUKOCYTE ANTIGEN; HEMOGLOBIN S; MYELOABLATIVE AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; DONOR; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; SIBLING; SICKLE CELL ANEMIA; SURVIVAL RATE; T CELL DEPLETION; UNRELATED DONORS; ALLOTRANSPLANTATION; ANEMIA, SICKLE CELL; CHEMISTRY; CHRONIC PAIN; COMPLICATION; CORD BLOOD STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN AGGREGATION, PATHOLOGICAL;

ANEMIA, SICKLE CELL; CHRONIC PAIN; CORD BLOOD STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN, SICKLE; HISTOCOMPATIBILITY TESTING; HUMANS; MYELOABLATIVE AGONISTS; PROTEIN AGGREGATION, PATHOLOGICAL; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84926509714     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12447     Document Type: Review

References (48)

1. Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT 3rd. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984;311:780-3.
2. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-76.
3. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol 2007;137:479-85.
4. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007;110:2749-56.
5. Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013;122:1072-8.
6. Dedeken L, Le PQ, Azzi N, Brachet C, Heijmans C, Huybrechts S, Devalck C, Rozen L, Ngalula M, Ferster A. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol 2014;165:402-8.
7. Maheshwari S, Kassim A, Yeh RF, et al. Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. Bone Marrow Transplant 2014;49:366-9.
8. Lucarelli G, Isgro A, Sodani P, et al. Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia. Bone Marrow Transplant 2014; doi: 10.1038/bmt.2014.167 [Epub ahead of print]
9. Nagel RL, Steinberg MH. Role of epistatic (modifier) genes in the modulation of the phenotypic diversity of sickle cell anemia. Pediatr Pathol Mol Med 2001;20:123-36.
10. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. Am J Hematol 2012;87:795-803.
11. Walters MC, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010;16:263-72.
12. Bodas P, Rotz S. Cerebral vascular abnormalities in pediatric patients with sickle cell disease after hematopoietic cell transplant. J Pediatr Hematol Oncol 2014;36:190-3.
13. Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J, Ware R, Leung W. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2013;19:820-30.
14. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000;95:1918-24.
15. Socie G, Salooja N, Cohen A, Rovelli A, Carreras E, Locasciulli A, Korthof E, Weis J, Levy V, Tichelli A. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003;101:3373-85.
16. Abikoff CM, Cairo MS. Reduced intensity conditioning and hematopoietic stem cell transplantation in pediatric nonmalignant disease: a new therapeutic paradigm. J Pediatr 2014;164:952-3 e2.
17. Bradley MB, Satwani P, Baldinger L, et al. Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseases. Bone Marrow Transplant 2007;40:621-31.
18. Del Toro G, Satwani P, Harrison L, et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004;33:613-22.
19. Geyer MB, Jacobson JS, Freedman J, et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011;155:218-34.
20. McGuinn C, Geyer MB, Jin Z, et al. Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia. Pediatr Blood Cancer 2014;61:1289-94.
21. Satwani P, Baldinger L, Freedman J, et al. Incidence of viral and fungal infections following busulfan-based reduced-intensity versus myeloablative conditioning in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2009;15:1587-95.
22. Satwani P, Bavishi S, Jin Z, Jacobson JS, Baker C, Duffy D, Lowe L, Morris E, Cairo MS. Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant. Biol Blood Marrow Transplant 2011;17:1472-80.
23. Satwani P, Harrison L, Morris E, Del Toro G, Cairo MS. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges. Biol Blood Marrow Transplant 2005;11:403-22.
24. Satwani P, Jin Z, Duffy D, et al. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant 2013;19:552-61.
25. Satwani P, Jin Z, Martin PL, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia 2014; doi: 10.1038/leu.2014.194. [Epub ahead of print]
26. Satwani P, Morris E, Bradley MB, Bhatia M, van de Ven C, Cairo MS. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 2008;50:1-8.
27. Styczynski J, Tallamy B, Waxman I, et al. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Bone Marrow Transplant 2011;46:790-9.
28. Krishnamurti L, Kharbanda S, Biernacki MA, Zhang W, Baker KS, Wagner JE, Wu CJ. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2008;14:1270-8.
29. Radhakrishnan K, Bhatia M, Geyer MB, Del Toro G, Jin Z, Baker C, Harrison L, Morris E, Baxter-Lowe LA, Cairo MS. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant 2013;19:676-7.
30. Kamani NR, Walters MC, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012;18:1265-72.
31. Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant 2014;49:913-20.
32. Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009;361:2309-17.
33. Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014;312:48-56.
34. Bazuaye N, Nwogoh B, Ikponmwen D, et al. First successful allogeneic hematopoietic stem cell transplantation for a sickle cell disease patient in a low resource country (Nigeria): a case report. Ann Transplant 2014;19:210-3.
35. Cairo MS, Rocha V, Gluckman E, Hale G, Wagner J. Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. Biol Blood Marrow Transplant 2008;14(1 Suppl 1):44-53.
36. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-66.
37. Liao Y, Geyer MB, Yang AJ, Cairo MS. Cord blood transplantation and stem cell regenerative potential. Exp Hematol 2011;39:393-412.
38. Adamkiewicz TV, Szabolcs P, Haight A, et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant 2007;11:641-4.
39. Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011;17:1375-82.
40. Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb LS Jr, Agarwal R, Weinberg KI, Wagner JE Jr. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells. Biol Blood Marrow Transplant 2014;20:581-6.
41. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120:4285-91.
42. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996;87:2082-8.
43. Sodani P, Isgro A, Gaziev J, et al. Purified T-depleted, CD34 + peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 2010;115:1296-302.
44. Freed J, Talano J, Small T, Ricci A, Cairo MS. Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'. Bone Marrow Transplant 2012;47:1489-98.
45. Talano J-A, Keever-Taylor C, Walters M, et al. Familial haploidentical (FHI) T-cell depleted (TCD) with T-cell addback stem cell transplantation for patients with high-risk sickle cell disease (SCD) (IND 14359). Biol Blood Marrow Transplant 2014;20:S135-6.
46. Abikoff C, Talano J-A, Keever-Taylor C, et al. Familial haploidentical (FHI) T-cell depleted (TCD) with T-cell addback stem cell transplantation for patients with high-risk sickle cell disease (SCD) (IND14359). ASH Annual Meeting; 2014 (abstract); 2014 (abstract).
47. Nickel RS, Hendrickson JE, Haight AE. The ethics of a proposed study of hematopoietic stem cell transplant for children with 'less severe' sickle cell disease. Blood 2014;124:861-6.
48. Shenoy S, Grossman WJ, DiPersio J, Yu LC, Wilson D, Barnes YJ, Mohanakumar T, Rao A, Hayashi RJ. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005;35:345-52.